West Nile virus immune globulin - Acambis/Cangene

Drug Profile

West Nile virus immune globulin - Acambis/Cangene

Alternative Names: West Nile Immune Globulin

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis; Cangene Corporation
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued West Nile virus infections

Most Recent Events

  • 26 Jun 2007 This programme remains on Cangene's pipeline but is a low priority.
  • 19 May 2004 Suspended - Preclinical for West Nile virus infections in Canada (unspecified route)
  • 19 May 2004 Suspended - Preclinical for West Nile virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top